Solumed Centrum Medyczne Sp. z o.o.
- Address
- Ul. Jana Henryka Dabrowskiego 77 A, 60-529 Poznan, Poland
Digestive System Diseases
At Solumed Centrum Medyczne Sp. z o.o. in Poznan, clinical research in Digestive System Diseases focuses on Crohn's disease and ulcerative colitis. These studies are designed to assess new treatment options, support long-term disease control, and better understand how therapies can help people with chronic inflammatory bowel conditions.
- Testing new therapies for Crohn's disease and ulcerative colitis
- Evaluating maintenance treatment and sustained symptom control
- Studying longer-term safety and treatment effectiveness
The site is actively involved in research aimed at improving care for patients living with ongoing intestinal inflammation and related digestive disorders.
Immune System Diseases
Research in Immune System Diseases at this site includes studies in moderate to severe plaque psoriasis, atopic dermatitis, and hidradenitis suppurativa. The trials are mainly focused on evaluating innovative therapies that may reduce inflammation, improve skin symptoms, and offer better long-term disease management.
- Investigating treatments for plaque psoriasis, atopic dermatitis, and hidradenitis suppurativa
- Assessing symptom improvement and disease control
- Exploring the safety and durability of new immune-targeted therapies
This therapeutic area reflects a strong emphasis on chronic inflammatory skin conditions where better control of flare-ups and sustained benefit are key goals.
Musculoskeletal Diseases
Within Musculoskeletal Diseases, the research portfolio includes psoriatic arthritis and hyperuricemia associated with gout. These clinical trials are intended to evaluate treatment effectiveness, help manage joint-related symptoms, and improve outcomes for patients affected by inflammatory or metabolic conditions involving the musculoskeletal system.
- Studying psoriatic arthritis linked to inflammatory skin disease
- Evaluating treatments for hyperuricemia associated with gout
- Measuring how well therapies reduce disease burden and support daily function
The work here connects joint health with broader immune and metabolic research, reflecting the overlap between systemic inflammation and musculoskeletal disease.
Nervous System Diseases
The site also conducts trials in Nervous System Diseases, mainly focused on migraine and menstrual migraine. These studies aim to test new approaches for both acute relief and prevention, with the goal of reducing attack frequency and improving quality of life for people affected by recurrent headaches.
- Research on migraine and menstrual migraine
- Evaluating therapies for immediate symptom relief and prevention
- Improving control of recurring headache disorders
This area highlights a focus on practical treatment options for patients seeking better day-to-day management of migraine-related symptoms.
Skin and Connective Tissue Diseases
Clinical trials in Skin and Connective Tissue Diseases at Solumed Centrum Medyczne Sp. z o.o. cover several inflammatory conditions, including moderate to severe plaque psoriasis, palmoplantar pustulosis, and hidradenitis suppurativa. The research is centered on testing emerging therapies, understanding how they affect skin inflammation, and supporting longer-term safety and tolerability.
- Studying inflammatory skin diseases such as psoriasis, palmoplantar pustulosis, and hidradenitis suppurativa
- Evaluating new treatments for disease control and symptom relief
- Assessing longer-term safety and patient benefit
This cluster of studies shows a strong dermatology focus, with research aimed at helping patients whose skin conditions can be persistent, painful, and difficult to manage.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Solumed Centrum Medyczne Sp. z o.o.
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis | Gilead Sciences Inc. | Phase II | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 2 | Unknown | 2024-04-03 | 2025-03-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
